文献速递眼底病与葡萄膜炎

渗出性年龄相关性黄斑变性玻璃体腔注射贝伐珠单抗后黄斑脉络膜体积变化

MACULAR CHOROIDAL VOLUME CHANGES AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
PubMed 文献 · Retina · 2017-01-01

研究纳入47例未治疗渗出性年龄相关性黄斑变性患者,每月玻璃体腔注射1.25 mg贝伐珠单抗共3次,采用增强深度成像光学相干断层扫描测量。第三次注射后1个月,黄斑脉络膜体积中位数从4.1 mm降至3.9 mm,黄斑中心凹下脉络膜厚度从157.0 μm降至139.0 μm,均P < 0.001。基线黄斑脉络膜体积与黄斑中心凹下脉络膜厚度均与治疗反应无关。

要点

  • 47例未治疗渗出性年龄相关性黄斑变性患者接受3次每月1.25 mg贝伐珠单抗注射。
  • 黄斑脉络膜体积中位数从4.1 mm降至3.9 mm,差异-0.46 mm,95%CI -0.57至0.35,P < 0.001。
  • 黄斑中心凹下脉络膜厚度从157.0 μm降至139.0 μm,P < 0.001。

核心结论

  • 3次每月贝伐珠单抗注射后,渗出性年龄相关性黄斑变性眼的黄斑脉络膜体积和黄斑中心凹下脉络膜厚度显著下降。

研究设计与样本

  • 纳入47例未治疗渗出性年龄相关性黄斑变性患者,平均年龄80 ± 6.4岁;采用增强深度成像光学相干断层扫描测量黄斑脉络膜体积和黄斑中心凹下脉络膜厚度;每例患者接受3次每月1.25 mg贝伐珠单抗玻璃体腔注射,第三次注射后1个月为最终评估。

主要发现

  • 黄斑脉络膜体积中位数从基线4.1 mm(四分位距3.4-5.9)降至最终检查3.9 mm(四分位距3.1-5.6),差异-0.46 mm,95%CI -0.57至0.35,P < 0.001。
  • 黄斑中心凹下脉络膜厚度从基线157.0 μm(四分位距116.0-244.5)降至最终检查139.0 μm(四分位距102.5-212.0),P < 0.001。
  • 基线黄斑脉络膜体积和基线黄斑中心凹下脉络膜厚度均与治疗反应无关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effect of intravitreal bevacizumab on the macular choroidal volume and the subfoveal choroidal thickness in treatment naïve eyes with exudative age-related macular degeneration. METHODS: The macular choroidal volume and the subfoveal choroidal thickness were measured using enhanced depth imaging optical coherence tomography. After a screening examination, each patient received 3 monthly intravitreal injections of 1.25 mg bevacizumab. One month after the third injection was a final assessment. RESULTS: Forty-seven patients with a mean age of 80 ± 6.4 years were included. The macular choroidal volume decreased significantly from median 4.1 mm (interquartile range 3.4-5.9) to median 3.9 mm (interquartile range 3.1-5.6) between the baseline and final examination (difference -0.46 mm, 95% confidence interval: -0.57 to 0.35, P < 0.001). Similarly, subfoveal choroidal thickness had decreased from 157.0 μm (interquartile range 116.0-244.5) at baseline to 139.0 μm (interquartile range 102.5-212.0) at the final examination (P < 0.001). Both parameters macular choroidal volume at baseline and subfoveal choroidal thickness at baseline were not associated with the response to treatment. CONCLUSION: The macular choroidal volume and the subfoveal choroidal thickness decreased significantly after 3 monthly bevacizumab injections for exudative age-related macular degeneration.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Palkovits S, Seidel G, Pertl L, et al. MACULAR CHOROIDAL VOLUME CHANGES AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina. 2017. PMID: 28129216. doi:10.1097/IAE.0000000000001480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。